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Abstract 
Haemophagocytic lymphohistiocytosis (HLH) is a rare and often fatal syndrome of abnormal 
T-cell activation and cytokine production, which can be familial or secondary in nature. 
Although HLH can occur concomitantly with lymphomas, the development of HLH 
alongside Hodgkin lymphoma in children is unusual. Here we report the diagnostic 
evaluation and clinical course of 2 paediatric cases of HLH secondary to lymphocyte-
depleted classical Hodgkin lymphoma. These cases highlight the need to be vigilant for this 
rare presentation and the difficulties in managing these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Haemophagocytic lymphohistiocytosis (HLH) is a rare and often fatal syndrome of hyper-
inflammation characterized by excessive activation of haemophagocytic macrophages, 
cytotoxic T-cells and natural killer (NK) cells. The resulting immune dysfunction leads to 
cytopenias, fever, hepatosplenomegaly and a down-regulation of the immune response
1
. HLH 
exists in two forms, either as a primary hereditary disease or as a secondary acquired 
condition
1
. 
The hereditary variant of HLH usually occurs in infancy but later presentation throughout 
childhood and young adulthood has been reported
2,3
. A variety of distinct genetic disorders 
and specific gene mutations including PRF1, UNC13D, STX11, and STXBP, have been 
described in hereditary HLH
4-7
.  These genes are important in controlling the exocytosis of 
cytotoxic granules, essential for normal natural killer (NK) cell and cytotoxic T-cell 
function
8,9
. In contrast, infection, malignancies, autoimmune disorders and immune 
deficiency syndromes can trigger secondary or acquired HLH.  
Epstein Barr virus (EBV) is the most frequently described viral trigger of HLH. EBV is 
predominantly a B lymphotrophic human γ-herpesvirus10. However, rarely infection of  NK 
and T cells has been observed and this is strongly associated with EBV-associated HLH
11
. 
Malignancy-associated HLH can be triggered by either the malignancy itself or following 
chemotherapy. T and NK cell lymphomas are the most frequently HLH-associated 
malignancies and also highly associated with EBV infection
12
.  Although secondary HLH is 
uncommon in B cell lymphomas there are numerous case reports describing an association 
with Hodgkin lymphoma (HL)
13-16
.  
HL exists as two distinct clinical entities: classical HL (cHL) and nodular lymphocyte 
predominant HL (NLPHL). The 2008 WHO classification further subdivides cHL into four 
subtypes; nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted 
classical Hodgkin lymphoma (LDCHL)
17
. EBV is implicated in the aetiology of HL with the 
degree of EBV association varying across subtypes. EBV onco-proteins are detectable in the 
Hodgkin Reed Sternberg (HRS) cells of LDCHL in over 90% of cases
17
. LDCHL is the rarest 
cHL subtype accounting for 1-5% of newly diagnosed cHL in western countries. There is a 
male preponderance with the median age at presentation between 30-37 years
17,18
. Although 
LDCHL can occur in the paediatric population it is extremely scarce. The UK based 
paediatric HD3 trial reported no cases of LDCHL
19
. Similarly only 16 cases are recorded in 
the SEER database (2002-2011)
20
. As a consequence of its rarity, definitive histopathological 
identification is often difficult and clinical characteristics, course and outcomes of paediatric 
patients with LDCHL is poorly understood.  
Due to the challenge of distinguishing HLH from other entities such as malignancy and 
infection determining underlying aetiology is difficult. Here, we report two cases of LDCHL 
occurring in childhood, complicated by developing HLH soon after initial presentation and 
commencement of chemotherapy. Literature describing childhood LDCHL-associated HLH 
is lacking and treatment recommendations for these children need to be determined. We 
discuss our experience of managing this distinct condition resulting from co-occurrence of 
two rare entities. 
Observations 
Case 1 
A previously fit and well five-year-old white Caucasian girl presented with a 4-week history 
of fever, lethargy and weight loss. At presentation, her haemoglobin measured 75 g/l, total 
white cell count 3.0 x10
9
/l (neutrophil count 1.8) and platelet count 53x10
9
/l. On examination 
she looked well but pale with a palpable spleen measuring 5 cm below the costal margin. 
Several diagnostic investigations were undertaken including a bone marrow aspirate which 
revealed no evidence of malignant infiltration or haemophagocytosis but mild dysplasia. 
Although the monospot screen for infectious mononucleosis was negative, EBV PCR on 
serum demonstrated 9192 copies/ml. She was also noted to have a normal triglyceride level 
of 1.25mmol/L but an elevated serum ferritin of 902 g/l (Figure 1). 
She received broad-spectrum antibiotics, piperacillin/tazobactam, but continued to be febrile. 
Although no infectious agent was identified, her antibiotics were empirically changed to 
meropenem. Over the course of a week, she developed tender hepatomegaly and mild splenic 
enlargement. Causes of primary liver failure were excluded.  
Further exploratory work-up included a CT neck-thorax-abdomen scan, which showed 
extensive lymphadenopathy prompting a lymph node biopsy. Pathology review reported total 
effacement of lymph node architecture by Hodgkin cells within a background of depleted 
lymphocytes and an increased number of histiocytes but no evidence of haemophagocytosis. 
The malignant cells co-expressed CD15, CD30 and PAX5 , classical immune-phenotypic 
markers of cHL and were EBER positive indicating EBV within the tumour. Thus the 
morphology and immunohistochemical analysis were consistent with a diagnosis of LDCHL. 
Further, lack of reactivity to CD20, CD3, CD8, CD4, CD43, CD2, CD5, CD45, EMA and 
ALK differentiated it from ALK negative anaplastic large cell lymphoma.  
The patient commenced prednisolone as part of OEPA (vincristine, etoposide, prednisolone 
and doxorubicin) induction regime for HL (EuroNet-PHL-C1, NCT00433459). Within 48hrs, 
she became significantly fluid overloaded, developed an oxygen requirement and acute 
respiratory distress. In view of progressive clinical deterioration, her steroids were switched 
to dexamethasone. A diagnosis of secondary HLH was made based on fever, splenomegaly, 
cytopenia, and elevated ferritin (Table 1)
21
. Although measurement of sCD25 was performed 
and showed marked elevation at 44736U/ml, this result was not available till after the clinical 
decision was made. In addition to sCD25, cytokine profiling showed significant derangement 
(Table 2). Immunosuppressive therapy was initiated and she received three doses of 
etoposide 125mg/m2 and cyclosporine, in accordance with the HLH-2004 protocol, 
NCT00426101).  
Despite changing therapy to treat HLH she continued to decline, developing tense ascites and 
disseminated intravascular coagulation. Her jaundice worsened with a marked conjugated 
hyperbilirubinaemia and a liver biopsy was done to aid diagnosis. The biopsy revealed 
scattered atypical cells and although not identified morphologically as classical Hodgkin 
Reed- Sternberg cells were strongly EBER positive and expressed CD15, CD30 and PAX5. 
Her clinical condition deteriorated rapidly over the next 24 hours leading to admission to the 
paediatric intensive care unit (PICU). There was no evidence of profound post-biopsy bleed, 
although she had significant coagulopathy and thrombocytopenia. She developed intractable 
hypotension and severe metabolic acidosis secondary to multi-organ dysfunction. Sadly, she 
died 30 days after initial presentation to our hospital. 
Case 2 
A fourteen-year-old boy of Pakistani origin presented to his local hospital with fever, 
jaundice, anaemia and lymphadenopathy. Prior to this he had been well but known to be 
glucose-6-phoshate dehydrogenase deficient with mild eczema and asthma. In other history 
of note, he recently travelled to Pakistan during which time he had been unwell with reports 
of a viral gastroenteritis. He was referred to the liver unit for investigation of his jaundice. 
Clinical examination confirmed jaundice and lymphadenopathy; in addition he had ascites, 
hepatosplenomegaly and a left-sided pleural effusion. Chest X-ray confirmed the pleural 
effusion and ultrasound imaging detected a liver lesion. Laboratory analysis indicated a 
pancytopenia, poor renal function and an elevated lactate dehydrogenase of 1110 IU/L. He 
was also IgG positive for Hepatitis A, consistent with a past infection.  
Within hours of presenting, he developed hypovolemic shock, worsening abdominal 
distension due to the ascites and fulminant respiratory failure resulting in admission to PICU. 
He required inotropic support for 5 days while his condition stabilized. Although febrile, 
blood cultures at presentation were negative with no infectious agent identified. He was 
empirically commenced on dexamethasone 6mg/m
2
/day, on suspicion there was an 
underlying malignant process. A bone marrow aspirate/trephine performed revealed multi-
focal infiltration of inter-trabecular spaces by EBER positive atypical cells co-expressing 
CD30 and PAX5 and an increased numbers of CD68 and CD163 positive macrophages were 
detected. 
Consistent with his bone marrow findings a lymph node biopsy revealed features suggestive 
of LDCHL. The neoplastic cells were positive for CD30, CD15, PAX5 and EBER and no 
reactivity for CD20, CD3, CD45, CD8, CD4, EMA, ALK, BCL-2 or CD10. He commenced 
OEPA induction regime for HL (EuroNet-PHL). However, this was changed to HLH-2004 
protocol the following day once his serum ferritin (8276 U/ml) and sCD25 (30624 U/ml) 
were known.  He fulfilled 6 of 8 criteria required for diagnosis of HLH: fever, splenomegaly, 
cytopenia, hypertriglyceridemia (4.21mmol/L), elevated ferritin and sCD25 (Table 1 and 
Figure 2)
21
. Further supporting the diagnosis of HLH, his cytokine profile was abnormal (IL-
10 680 pg/ml, IL-6 115 pg/ml, TNF-α 130 pg/ml) (Table 2). His EBV PCR on admission was 
6104 copies/ml, which had risen to 39265 copies/ml before he commenced the HLH-2004 
protocol. 
He continued to need PICU support for his multi-organ failure and coagulopathy. Over the 
following week he appeared to stabilise and made sufficient improvement that he returned to 
the main ward. A clinical decision was made to add rituximab to his treatment regime, which 
he tolerated well. Despite an apparent response to his treatment with a fall in his serum 
ferritin, he succumbed to sepsis and died 35 days after admission. Both candida and 
enterococcus were isolated in extended blood cultures. 
Discussion 
Malignancy-associated HLH is well described in the paediatric population but to our 
knowledge this is the first report of paediatric LDCHL-associated HLH. Across 3 recent 
retrospective studies of malignancy-associated HLH in children and adolescents, only 4 out 
of a total of 72 patients were documented to have cHL-associated HLH (2 nodular sclerosis, 1 
lymphocyte-predominant, 1 subtype not specified)
22-24
. This is possibly, in part, due to the 
rarity of LDCHL in children. There are only limited clinical descriptions of children with 
LDCHL in the literature. In adults, LDCHL compared with other HL subtypes, present more 
frequently with unfavourable characteristics such as advanced stage, involvement of bone 
marrow and liver and B symptoms.  A small study of 310 adult patients, 29 were LDCHL and 
these patients had an inferior outcome, five-year overall survival: 29% vs. 86% (P<0.001)
12
. 
A much larger German series of 10,019 adult patients identified 84 patients with LDCHL and 
reported 5 years OS, 83% v 92% (p=0.0018) in LDCHL compared with patients with other 
HL subtypes
18
.  
A delay in recognition of lymphoma-associated HLH is not uncommon as HLH 
manifestations may be indiscernible from the lymphoma or HLH precedes the diagnosis of 
malignancy. Furthermore, in secondary HLH pathognomonic haemophagocytosis may not be 
seen until the disease progresses. However, abnormal serum ferritin, triglyceride and 
fibrinogen levels should raise suspicion and prompt measurement of sCD25. In an analysis of 
sCD25 in cHL subtypes without evidence of HLH, patients with LDCHL had significantly 
higher sCD25 (median: 8240 U/ml in LDCHL patients compared to 1705 U/ml in non-
LDCHL patients)
12
. Interestingly, both patients reported here had exceedingly high sCD25, 
more than 10-fold above the minimum level for diagnosis of HLH. Such high sCD25 levels 
may serve, as a useful indicator that a patient with LDCHL is atypical and complicated by 
concomitant HLH. Similarly, although serum ferritin is non-specifically raised in many 
inflammatory conditions, in paediatric patients, high levels are most commonly associated 
with HLH
25
. Notably, the second patient presented with a higher ferritin compared to the first 
patient, possibly correlating with the severity of HLH, hence rapid clinical progression and 
onset of HLH seen. 
Rituximab, a monoclonal antibody to CD20, is standard therapy to treat many B-cell 
malignancies
26,27
. However, HRS cells despite their B cell origin do not express typical B-cell 
lineage markers including CD20
28
. We opted to add rituximab to the treatment for Case 2 as; 
1) rituximab has been reported to be effective in EBV associated HLH
29
 and 2) rituximab 
may also have therapeutic value in patients with cHL
30,31
. In cHL, rituximab is hypothesized 
to work by either depleting reactive B lymphocytes from the microenvironment, which may 
enhance antitumor immunity, or by killing the putative CD20-expressing HL stem cells. 
However as rituximab does not deplete the T cell or NK cell pool it is unlikely to be effective 
as a single agent. 
HLH is often refractory to therapy and carries a high mortality rate. In the paediatric 
population, there is little evidence-based medicine to guide clinical decisions in the 
management of refractory malignancy-associated HLH and none for LDCHL-associated 
HLH. Salvage strategies from individual case reports aim to either, control the cytokine storm 
by removal of cytokines via plasmapheresis
32
 or use targeted therapies against immune cell 
subsets. Both our patients were haemodynamically unstable with coagulopathy making 
plasmapheresis a risky procedure for uncertain benefit.  
Daclizumab, a monoclonal antibody against CD25 has been used with success in paediatric-
HLH on an individual basis
33
. In this case daclizumab was administered alongside other 
cytotoxic and immunosuppressive agents making it difficult to determine which drug was 
responsible for the observed clinical improvement. However, given the extremely high levels 
of soluble CD25 in our patients it is possible that daclizumab could have proven useful. 
CD25 is also an attractive target in cHL as it is expressed in both a minority of HRS
34
 cells 
but also on regulatory T cell, abundant in the tumour microenvironment
35
. Anti-CD25 drug 
conjugates have been trialled in refractory/relapsed Hodgkin with evidence of activity
36,37
. 
However, daclizumab has been withdrawn from the market following a number of patients 
with multiple sclerosis developing immune-mediated encephalitis after receiving the drug
38
. 
A second monoclonal antibody, alemtuzumab that targets CD52 on lymphocytes, monocytes, 
macrophages and dendritic cells has been also tested
39
. The primary indication of 
alemtuzumab is in the treatment of chronic lymphocytic leukaemia
40
 and multiple 
sclerosis
41,42
. However, a retrospective study of alemtuzumab use in 22 paediatric and adult 
patients with refractory HLH found at least 64% had some improvement
39
. Patients had a 
received variety of therapies before initiation of alemtuzumab, which was given in a range of 
dosing schedules. The most significant complication in that study was high incidence of 
viremias following alemtuzumab, in particular reactivation of cytomegalovirus
39
. The high 
EBV viral load of our patients made us cautious against alemtuzumab.   
A number of reports also suggested targeting inflammation by blocking the tumor necrosis 
factor (TNF) axis using either infliximab an anti-TNF-alpha monoclonal antibody or the TNF 
inhibitor, etanercept
43
. These agents are used to treat inflammatory bowel disease and 
historically clinicians were concerned with the risk of developing lymphoma and HLH in 
patients who received such therapy. However, a large prospective study of 5766 patients 17-
years old or younger found no increased risk of HLH associated with infliximab
44
. Infliximab 
certainly warrants further study in the context refractory paediatric-HLH. 
A delay in the diagnosis of HLH often proves to be catastrophic and it is important for 
clinicians to be alert to its possibility. The two children at our centre showed rapid 
deterioration and were in extremis at the point of commencement of immunosuppressive 
therapy.  The triad of lymphoma, high EBV load and HLH in our patients posed a number of 
challenges from diagnosis to therapeutic management. A lack of prospective, randomized or 
controlled clinical trials in malignancy-associated HLH makes it difficult to determine 
whether an HLH-directed, malignancy-directed or combined approach should be adopted. 
Although the treatment regimes do often overlap for example etoposide used in induction 
chemotherapy for cHL is also proven to be beneficial in EBV-associated HLH as well as part 
of HLH-2004 protocol. However, the best therapeutic options in refractory-HLH still need to 
be determined for children and adults alike.  
  
Table 1 Diagnostic criteria for HLH
21
  
The diagnosis HLH can be established if one of either 1 or 2 below is fulfilled 
 
1 A molecular diagnosis consistent with HLH 
2 Diagnostic criteria for HLH fulfilled (five out of the eight criteria below) 
 Fever (peak temperature of > 38.5° C for > 7 days) 
 Splenomegaly (spleen palpable > 3 cm below costal margin) 
 Cytopenia involving > 2 cell lines (Hb < 9 g/dL, absolute neutrophil count < 100/μL, 
platelets < 100,000/μL) 
 Hypertriglyceridemia (fasting triglycerides > 2.0 mmol/L or > 3 standard deviations 
[SD] more than normal value for age) or hypofibrinogenemia (fibrinogen < 1.5 g/L or > 
3 SD less than normal value for age) 
 Hemophagocytosis (in biopsy samples of bone marrow, spleen, or lymph nodes) 
 Low or absent natural killer cell activity 
 Serum ferritin > 500 μg/L 
 Elevated soluble interleukin-2 (CD25) levels (>2400 U/mL or very high for age) 
 
Table 2 Summary of cytokine profile 
Cytokine and sCD25 Case 1 Case 2 Reference 
sCD25 U/ml 44736 30624 200-500 
IL-10 pg/ml 10000 680 <3 
IL-1β pg/ml 19.8 10.5 <5 
IL-6 pg/ml 346 115 <6 
IL-8 pg/ml 64.5 5.66 <70 
TNF-a pg/ml 60.8 130 <3 
EPO mU/ml 7.49 40 <30 
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Figure Legends 
Figure 1: Schematic showing the serum concentrations of bilirubin, triglyceride and ferritin, 
as well as the EBV copy number in Case 1, alongside treatment. 
 
Figure 2: Schematic showing the serum concentrations of bilirubin, triglyceride, ferritin and 
sCD25, as well as the EBV copy number in Case 2, alongside treatment. 
 
 
 
 
 
 
